Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?
C RosemanJohan Karlsson WallmanAnna JöudMaria E C SchelinJon Thorkell EinarssonElisabet LindqvistJon LampaMeliha Crnkic KapetanovicTor OlofssonPublished in: Scandinavian journal of rheumatology (2023)
A substantial proportion of PsA patients reported unacceptable pain throughout the first anti-TNF treatment year. At 12 months, refractory pain constituted about two-thirds of this remaining pain load. More objective signs of inflammation at anti-TNF initiation were associated with less future refractory pain. This highlights insufficient effect of biologics in patients with inflammation-independent pain, warranting alternative treatments.